Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

93 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Successful response to tralokinumab in patients unresponsive, intolerant or with contraindications to dupilumab and JAK inhibitors: A case series.
Gori N, Ippoliti E, Ferrucci SM, Balato A, Ortoncelli M, Maurelli M, Galluzzo M, Munera Campos M, Seremet T, Di Nardo L, Antonelli F, Coscarella G, Conrad C, Carrascosa JM, Bianchi L, Argenziano G, Ribero S, Girolomoni G, Marzano AV, Chiricozzi A, Peris K; MEDaCoTRA Study Group. Gori N, et al. J Eur Acad Dermatol Venereol. 2024 Oct;38(10):e852-e854. doi: 10.1111/jdv.19929. Epub 2024 Feb 29. J Eur Acad Dermatol Venereol. 2024. PMID: 38421043 No abstract available.
Eczematous liraglutide eruption managed by dupilumab: A case report.
Paganini C, Belcastro A, Fico A, Talamonti M, Bianchi L, Galluzzo M. Paganini C, et al. JAAD Case Rep. 2024 Sep 2;53:57-59. doi: 10.1016/j.jdcr.2024.08.018. eCollection 2024 Nov. JAAD Case Rep. 2024. PMID: 39430632 Free PMC article. No abstract available.
93 results